vs
Certara, Inc.（CERT）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Certara, Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.5倍（$103.6M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -5.7%，领先389.7%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 3.3%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 3.6%）
Certara是全球领先的生物制药软件及咨询服务提供商，专注于建模模拟、监管科学领域的解决方案，服务药企、生物技术企业及医疗相关方，覆盖药物研发全周期，助力加快新疗法上市，降低研发风险与综合成本。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CERT vs RIGL — 直观对比
营收规模更大
CERT
是对方的1.5倍
$69.8M
营收增速更快
RIGL
高出17.9%
3.3%
净利率更高
RIGL
高出389.7%
-5.7%
两年增速更快
RIGL
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $103.6M | $69.8M |
| 净利润 | $-5.9M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 0.8% | 33.2% |
| 净利率 | -5.7% | 384.0% |
| 营收同比 | 3.3% | 21.2% |
| 净利润同比 | -189.6% | 1769.2% |
| 每股收益（稀释后） | $-0.04 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CERTRIGL
| Q4 25 | $103.6M | $69.8M | ||
| Q3 25 | $104.6M | $69.5M | ||
| Q2 25 | $104.6M | $101.7M | ||
| Q1 25 | $106.0M | $53.3M | ||
| Q4 24 | $100.4M | $57.6M | ||
| Q3 24 | $94.8M | $55.3M | ||
| Q2 24 | $93.3M | $36.8M | ||
| Q1 24 | $96.7M | $29.5M |
净利润CERTRIGL
| Q4 25 | $-5.9M | $268.1M | ||
| Q3 25 | $1.5M | $27.9M | ||
| Q2 25 | $-2.0M | $59.6M | ||
| Q1 25 | $4.7M | $11.4M | ||
| Q4 24 | $6.6M | $14.3M | ||
| Q3 24 | $-1.4M | $12.4M | ||
| Q2 24 | $-12.6M | $-1.0M | ||
| Q1 24 | $-4.7M | $-8.2M |
毛利率CERTRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率CERTRIGL
| Q4 25 | 0.8% | 33.2% | ||
| Q3 25 | 2.9% | 40.9% | ||
| Q2 25 | 9.1% | 60.1% | ||
| Q1 25 | 7.2% | 23.9% | ||
| Q4 24 | 6.0% | 28.9% | ||
| Q3 24 | 2.7% | 25.4% | ||
| Q2 24 | -9.7% | 1.2% | ||
| Q1 24 | -1.3% | -23.6% |
净利率CERTRIGL
| Q4 25 | -5.7% | 384.0% | ||
| Q3 25 | 1.5% | 40.2% | ||
| Q2 25 | -1.9% | 58.6% | ||
| Q1 25 | 4.5% | 21.5% | ||
| Q4 24 | 6.6% | 24.9% | ||
| Q3 24 | -1.4% | 22.5% | ||
| Q2 24 | -13.5% | -2.8% | ||
| Q1 24 | -4.8% | -27.9% |
每股收益（稀释后）CERTRIGL
| Q4 25 | $-0.04 | $14.11 | ||
| Q3 25 | $0.01 | $1.46 | ||
| Q2 25 | $-0.01 | $3.28 | ||
| Q1 25 | $0.03 | $0.63 | ||
| Q4 24 | $0.04 | $0.82 | ||
| Q3 24 | $-0.01 | $0.70 | ||
| Q2 24 | $-0.08 | $-0.06 | ||
| Q1 24 | $-0.03 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $189.4M | $155.0M |
| 总债务越低越好 | $293.1M | $52.5M |
| 股东权益账面价值 | $1.1B | $391.5M |
| 总资产 | $1.6B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.28× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CERTRIGL
| Q4 25 | $189.4M | $155.0M | ||
| Q3 25 | $172.7M | $137.1M | ||
| Q2 25 | $162.3M | $108.4M | ||
| Q1 25 | $179.1M | $77.1M | ||
| Q4 24 | $179.2M | $77.3M | ||
| Q3 24 | $233.0M | $61.1M | ||
| Q2 24 | $224.6M | $49.1M | ||
| Q1 24 | $224.8M | $49.5M |
总债务CERTRIGL
| Q4 25 | $293.1M | $52.5M | ||
| Q3 25 | $293.5M | $60.0M | ||
| Q2 25 | $294.2M | $60.0M | ||
| Q1 25 | $294.8M | $60.0M | ||
| Q4 24 | $295.4M | $60.0M | ||
| Q3 24 | $296.1M | $60.0M | ||
| Q2 24 | $296.7M | $60.0M | ||
| Q1 24 | $290.8M | $60.0M |
股东权益CERTRIGL
| Q4 25 | $1.1B | $391.5M | ||
| Q3 25 | $1.1B | $117.6M | ||
| Q2 25 | $1.1B | $81.9M | ||
| Q1 25 | $1.1B | $18.6M | ||
| Q4 24 | $1.1B | $3.3M | ||
| Q3 24 | $1.1B | $-14.6M | ||
| Q2 24 | $1.0B | $-29.9M | ||
| Q1 24 | $1.1B | $-31.7M |
总资产CERTRIGL
| Q4 25 | $1.6B | $513.6M | ||
| Q3 25 | $1.5B | $242.5M | ||
| Q2 25 | $1.5B | $206.7M | ||
| Q1 25 | $1.6B | $176.0M | ||
| Q4 24 | $1.6B | $164.0M | ||
| Q3 24 | $1.5B | $139.4M | ||
| Q2 24 | $1.5B | $128.4M | ||
| Q1 24 | $1.5B | $126.5M |
负债/权益比CERTRIGL
| Q4 25 | 0.28× | 0.13× | ||
| Q3 25 | 0.28× | 0.51× | ||
| Q2 25 | 0.27× | 0.73× | ||
| Q1 25 | 0.27× | 3.23× | ||
| Q4 24 | 0.28× | 18.25× | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | 0.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.8M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $27.8M | — |
| 自由现金流率自由现金流/营收 | 26.8% | — |
| 资本支出强度资本支出/营收 | 1.0% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $94.4M | — |
8季度趋势，按日历期对齐
经营现金流CERTRIGL
| Q4 25 | $28.8M | $22.0M | ||
| Q3 25 | $32.3M | $24.0M | ||
| Q2 25 | $17.8M | $30.5M | ||
| Q1 25 | $17.4M | $-893.0K | ||
| Q4 24 | $49.4M | $14.5M | ||
| Q3 24 | $17.0M | $21.7M | ||
| Q2 24 | $9.8M | $302.0K | ||
| Q1 24 | $4.3M | $-5.0M |
自由现金流CERTRIGL
| Q4 25 | $27.8M | — | ||
| Q3 25 | $32.1M | — | ||
| Q2 25 | $17.8M | — | ||
| Q1 25 | $16.8M | — | ||
| Q4 24 | $49.0M | — | ||
| Q3 24 | $16.8M | — | ||
| Q2 24 | $9.4M | — | ||
| Q1 24 | $3.7M | — |
自由现金流率CERTRIGL
| Q4 25 | 26.8% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | 17.0% | — | ||
| Q1 25 | 15.8% | — | ||
| Q4 24 | 48.8% | — | ||
| Q3 24 | 17.7% | — | ||
| Q2 24 | 10.1% | — | ||
| Q1 24 | 3.8% | — |
资本支出强度CERTRIGL
| Q4 25 | 1.0% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 0.6% | — |
现金转化率CERTRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | 21.19× | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | 3.66× | -0.08× | ||
| Q4 24 | 7.51× | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
